Organogenesis Holdings Inc.
ORGO Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.94
KIRA · Stoqly’s AI analyst, in plain words
- Organogenesis Holdings Inc. had $564M of revenue in fiscal 2025, up 17.0% on the year before. Over five years, revenue changed +10.8% a year on average.
- Its operating margin was 7.9%, up 8.2 pts: of every 100 in sales, about 8 is left after running the business.
- Organogenesis Holdings Inc. made $37.0M of net profit in fiscal 2025.
- Free cash flow was −$24.5M in fiscal 2025, −4.3% of revenue.
Market cap
$120M
P/E
—
Revenue
$564M
Net income
$37.0M
Free cash flow
−$24.5M
Operating margin
7.9%
Organogenesis Holdings Inc. in 30 seconds · fiscal 2025
Are sales growing?
+17.0%
Yes. Sales grew 17.0% last year.
Does it make a profit?
6.6%
A little. It keeps 6.6% of every sale as profit.
Does profit turn into cash?
−4.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Organogenesis Holdings Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- Organogenesis Holdings Inc.
- CIK
- 0001661181
Organogenesis Holdings Inc. · ORGO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $467M | $451M | $433M | $482M | $564M |
| Revenue growth | 38.2% | −3.5% | −3.9% | 11.3% | 17.0% |
| Gross margin | 75.6% | 76.7% | 75.4% | 76.0% | — |
| Operating margin | 15.5% | 4.9% | 2.9% | −0.3% | 7.9% |
| Net income | $94.2M | $15.5M | $4.9M | $0.9M | $37.0M |
| Net margin | 20.2% | 3.4% | 1.1% | 0.2% | 6.6% |
| Diluted EPS | $0.70 | $0.12 | $0.04 | −$0.01 | $0.15 |
| Cash | |||||
| Cash from operations | $62.0M | $24.9M | $30.9M | $14.2M | −$10.3M |
| Capital expenditure | $31.2M | $33.9M | $24.4M | $10.0M | $14.2M |
| Free cash flow | $30.8M | −$9.0M | $6.6M | $4.2M | −$24.5M |
| FCF margin | 6.6% | −2.0% | 1.5% | 0.9% | −4.3% |
| Share buybacks | — | $0.0M | $0.0M | $25.5M | — |
| Share count change | 20.0% | −1.0% | 0.3% | −0.8% | −1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $114M | $102M | $104M | $136M | $93.7M |
| Debt incl. finance leases | $74.3M | $71.3M | $69.5M | — | — |
| Shareholders' equity | $241M | $266M | $279M | $263M | $300M |
| Net debt / EBITDA | −0.5x | −1.1x | −1.5x | — | — |
| Current ratio | 2.7x | 3.0x | 2.8x | 3.7x | 3.6x |
| Interest coverage | 10.0x | 11.1x | 5.7x | −0.8x | — |
| Returns and quality | |||||
| Return on capital | 35.8% | 7.3% | 3.4% | — | — |
| Return on equity | 49.2% | 6.1% | 1.8% | 0.3% | 13.2% |
| Return on tangible equity | 50.8% | 7.2% | 2.1% | −0.4% | 7.6% |
| Piotroski F-score | 6 | 7 | 4 | 7 | 3 |
| Altman Z'' | 4.0 | 3.7 | 3.6 | 4.9 | 5.3 |
Insiders bought, 12 months
$0.0M
2 insiders
Insiders sold, 12 months
$2.6M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Organogenesis Holdings Inc. · ORGO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.94 a share, the company is worth $120M.
Source: SEC EDGAR XBRL filings (CIK 0001661181). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.